Oncolytics Biotech Inc (ONCY)
Oncolytics Biotech develops pelareorep, an experimental intravenous cancer therapy for gastrointestinal tumors. It last closed at $0.35 on Nov 20, down 10.37% on the day. Over the last 12 months ONCY insiders bought $363K of stock on the open market and sold $0, according to SEC Form 4 filings.
Key Stats
Fiscal 2024Not reported for this period.
From ONCY's SEC filings, latest 10-Q for the period ending Dec 31, 2024 (filed Nov 13). Figures are in CAD. Per share figures are left out because the US listing can represent a different number of shares.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →StreetAlpha's curated list of analyst calls collected from around the web. It may be incomplete or inaccurate, is not a consensus and is not advice.
- Every upgrade, downgrade and initiation as it happens
- Every price target change, raised or cut
- Consensus rating with the average, high and low targets
- Each firm's full rating history on ONCY
Technical AnalysisPrices may be delayed
The stock is 17% below its 20 day and 53% below its 50 day average. It is 133% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 37), near oversold. The nearest support is the 52 week low at $0.33, and the nearest resistance the Pivot at $0.36.
| RSI (14) | 37.28 | Weak, oversold below 30 | Neutral |
| MACD | -0.04 | Above its signal line | Bullish |
| Stochastic | 47.2 | Middle of its range | Neutral |
| ADX (14) | 35.8 | Trending down | |
| Williams %R | -86.9 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -124.2 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −20.3% | Change over 10 sessions | Bearish |
| ATR (14) | $0.05 | Typical daily range, 14.4% of price |
| RSI (14) | 26.90 | Oversold below 30 | Oversold |
| MACD | -0.14 | Below its signal line | Bearish |
| Stochastic | 6.6 | Near the bottom of its range | Oversold |
| ADX (14) | 21.7 | Weak trend | |
| Williams %R | -97.1 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -128.0 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −53.0% | Change over 10 sessions | Bearish |
| ATR (14) | $0.12 | Typical daily range, 35.2% of price |
What happened before
See how ONCY did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How ONCY has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2005.
Whale Options FlowPrices may be delayed
90DNo whale options trades in ONCY in the last 90 days.
ONCY Institutional Ownership
Full report →- ▲29 buying vs 23 selling
- ▼Held by funds -0.7 pts
- ▲Funds holding +2
- ▼Superinvestors: 1 added, 2 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 77 | 75 | +2.7% |
| In funds' top 10 | 0 | 0 | – |
| Held by funds | 2.4% | 3.1% | −0.7 pts |
| New / increased | 10 / 19 | 72 / 0 | −59.7% |
| Reduced / sold out | 14 / 9 | 1 / 1 | +1050.0% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
ONCY Insider Trading
All filings →| Trade date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 12 | Jared KellyCEO | Buy | 5,050 | $0.96 | $5K |
| Mar 11 | James T. ParsonsDirector | Buy | 10,000 | $1.03 | $10K |
| Feb 12 | Jared KellyCEO | Buy | 35,100 | $0.84 | $29K |
| Feb 12 | Bernd R. SeizingerDirector | Buy | 100,000 | $0.84 | $84K |
| Feb 12 | Patricia S AndrewsDirector | Buy | 35,400 | $0.86 | $30K |
| Feb 12 | Deborah Margaret BrownDirector | Buy | 25,000 | $0.85 | $21K |
From SEC Form 4 filings by ONCY's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper tradingStreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ONCY is in one of them and how their past ONCY trades turned out.
ONCY News Tone and PricePrices may be delayed
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ONCY in an article yet. Here's the latest on the wider market.
- Oncolytics Biotech ® Announces Clinical Supply Agreement to Evaluate Pelareorep in Combination with LOQTORZI ® (toripalimab-tpzi) in Squamous Cell Anal Carcinoma
- Pelareorep Induces Coordinated Antiviral Immune Responses and Enhanced Antitumor Immunity in Multiple Myeloma Patients
- Translational Data from Anal Cancer Patients Show Pelareorep Drives HPV-Specific Immune Responses, Supporting its Potential Across HPV-Driven Cancers
- Oncolytics Biotech ® Reports Strong Durability and Survival Data in Anal Cancer, Positioning Pelareorep as Potential Backbone Immunotherapy Across HPV-Driven Cancers
About Oncolytics Biotech
Oncolytics Biotech is a biopharmaceutical company based in San Diego, California. It is developing pelareorep, an experimental cancer therapy given intravenously that is made from a common virus that does not cause disease. The company is testing pelareorep alone and with other cancer treatments, mainly for gastrointestinal cancers, and plans to partner with larger drug companies. Its intended customers are cancer patients and the doctors who treat them.
- Headquarters
- San Diego, CA
- Founded
- 1998
- Website
- oncolyticsbiotech.com ↗


